EA201301308A1 - Комбинация для лечения сахарного диабета - Google Patents

Комбинация для лечения сахарного диабета

Info

Publication number
EA201301308A1
EA201301308A1 EA201301308A EA201301308A EA201301308A1 EA 201301308 A1 EA201301308 A1 EA 201301308A1 EA 201301308 A EA201301308 A EA 201301308A EA 201301308 A EA201301308 A EA 201301308A EA 201301308 A1 EA201301308 A1 EA 201301308A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
treatment
diabetes mellitus
dissociating
sugar
Prior art date
Application number
EA201301308A
Other languages
English (en)
Other versions
EA028394B1 (ru
Inventor
Сергей Юрьевич Лешков
Нина Сергеевна Вихриева
Сергей Петрович Кречетов
Original Assignee
Сергей Юрьевич Лешков
Нина Сергеевна Вихриева
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сергей Юрьевич Лешков, Нина Сергеевна Вихриева filed Critical Сергей Юрьевич Лешков
Publication of EA201301308A1 publication Critical patent/EA201301308A1/ru
Publication of EA028394B1 publication Critical patent/EA028394B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Medical Informatics (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложена комбинация для лечения сахарного диабета, которая может быть выполнена в виде фармацевтической композиции или фармацевтического набора. Комбинация содержит сахароснижающие средства и природные фенольные соединения, способные к разобщению окислительного фосфорилирования. Такая комбинация позволяет снизить возможность появления побочных эффектов от применения сахароснижающих препаратов и, в частности, риск развития лактатного ацидоза.
EA201301308A 2011-06-02 2012-04-05 Комбинация для лечения сахарного диабета EA028394B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011122374/15A RU2451506C1 (ru) 2011-06-02 2011-06-02 Комбинация для лечения сахарного диабета и его осложнений
PCT/RU2012/000254 WO2012166008A1 (en) 2011-06-02 2012-04-05 Combination for treatment of diabetes mellitus

Publications (2)

Publication Number Publication Date
EA201301308A1 true EA201301308A1 (ru) 2014-03-31
EA028394B1 EA028394B1 (ru) 2017-11-30

Family

ID=46231593

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301308A EA028394B1 (ru) 2011-06-02 2012-04-05 Комбинация для лечения сахарного диабета

Country Status (7)

Country Link
EP (1) EP2714022A1 (ru)
JP (1) JP2014527506A (ru)
KR (1) KR101567660B1 (ru)
CN (1) CN103402506A (ru)
EA (1) EA028394B1 (ru)
RU (1) RU2451506C1 (ru)
WO (1) WO2012166008A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548731C2 (ru) * 2012-10-24 2015-04-20 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" Средство и способ комплексной терапии больных сахарным диабетом
CA2912881A1 (en) 2013-05-24 2014-11-27 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
US10442610B2 (en) 2014-03-11 2019-10-15 Starbucks Corporation Pod-based restrictors and methods
CN105902761A (zh) * 2016-06-16 2016-08-31 河南中医学院 一种槐花珍在制备治疗高血糖和糖尿病药物中的应用
FR3062795B1 (fr) * 2017-02-16 2019-06-07 Valbiotis Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal.
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399658B1 (en) * 1996-12-24 2002-06-04 Sumitomo Pharmaceuticals Co., Ltd. Composition containing ascorbic acid
PT974356E (pt) 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
ITMI20002019A1 (it) 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
JP4719372B2 (ja) * 2000-06-21 2011-07-06 花王株式会社 Ｐｐａｒ依存的遺伝子転写活性化剤
DE60135760D1 (de) * 2000-08-01 2008-10-23 Oryza Oil & Fat Chem Nachtkerzensamenextrakte als inhibitoren der zuckerabsorption und deren herstellungsprozess
JP2003300904A (ja) * 2002-04-05 2003-10-21 National Cardiovascular Center 循環器系障害の進展を抑制する医薬組成物
KR20060121887A (ko) * 2003-09-23 2006-11-29 디에스엠 아이피 어셋츠 비.브이. 진성 당뇨병의 치료 및 예방용 조성물
US20070099826A1 (en) * 2003-10-10 2007-05-03 Norman Wong Treatment of diseases associated with the egr-1 enhancer element
RU2284829C2 (ru) * 2004-12-16 2006-10-10 Пятигорская государственная фармацевтическая академия Антидиабетический сбор
WO2006079056A1 (en) * 2005-01-20 2006-07-27 Stephen Holt Herbal compositions containing hoodia
CA2615118A1 (en) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar.gamma. agonist
JP5246833B2 (ja) * 2005-12-16 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生増強剤
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤
CN101176786A (zh) * 2006-11-08 2008-05-14 中国科学院上海生命科学研究院 增加胰岛素敏感性的方法和组合物
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
TW200903710A (en) 2007-07-11 2009-01-16 Promos Technologies Inc Manufacturing method for shallow trench isolation
US20090175973A1 (en) * 2007-09-05 2009-07-09 Nina Vikhrieva Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders
CN101250106B (zh) * 2008-03-27 2011-05-18 北京市农林科学院 一种提取绿原酸的方法
JP5054594B2 (ja) * 2008-03-31 2012-10-24 花王株式会社 脂質代謝改善剤
RU2378003C1 (ru) 2008-06-06 2010-01-10 Сергей Юрьевич Лешков Фармацевтическая композиция на основе экстракта зеленой ягоды кофе, способ получения и применения
WO2010048114A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
WO2010089874A1 (ja) * 2009-02-05 2010-08-12 フジッコ株式会社 ＰＰＡＲ－γ発現増強剤、アディポネクチン産生促進剤、ＵＣＰ活性剤およびそれらを用いた医薬品・飲食品
EP2418965B1 (en) * 2009-04-17 2016-06-29 DSM IP Assets B.V. Hydroxytyrosol combinations for enhancing mitochondrial function and energy production.
EP2432320A4 (en) * 2009-05-20 2013-03-06 Nutracryst Therapeutics Private Ltd PHARMACEUTICAL CO-CRYSTALS OF QUERCÉTINE
JP2011063557A (ja) * 2009-09-18 2011-03-31 Lion Corp Ｐｐａｒ活性化剤
ES2356536B1 (es) * 2009-09-23 2012-02-13 Probelte Pharma, Sa Una composición de uso como prebiótico que contiene un extracto de granada y un alimento que incluye dicha composición.
CN101851221B (zh) * 2010-05-27 2012-09-05 东北林业大学 一种从落叶松中制备二氢槲皮素的方法

Also Published As

Publication number Publication date
CN103402506A (zh) 2013-11-20
WO2012166008A1 (en) 2012-12-06
RU2451506C1 (ru) 2012-05-27
EA028394B1 (ru) 2017-11-30
JP2014527506A (ja) 2014-10-16
EP2714022A1 (en) 2014-04-09
KR20140008452A (ko) 2014-01-21
KR101567660B1 (ko) 2015-11-10

Similar Documents

Publication Publication Date Title
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
EA201301308A1 (ru) Комбинация для лечения сахарного диабета
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2013000716A1 (es) Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2.
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
EA201290919A1 (ru) Индазольные соединения и их применение
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
EA201391028A1 (ru) Гиполипидемическое противодиабетическое средство
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
EA201201623A1 (ru) Лечение диабета 2 типа
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU